Targeted anticancer effect through microRNA-181a regulated tumor-specific hTERT replacement

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 918-928

  Won, You Sub ^a   Jeong, Jin Sook ^b   Kim, Sung Jin ^a   Ju, Mi Ha ^b   Lee, Seong Wook ^a  

^a Department of Molecular Biology Institute of Nanosensor and Biotechnology Research Institute of Advanced Omics   (South Korea)

^b Dong A University College of Medicine   (South Korea)

Author keywords

Cancer gene therapy; HTERT; MicroRNA 181a; RNA replacement; Trans splicing ribozyme

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; MICRORNA; MICRORNA 181A; RIBOZYME; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; MESSENGER RNA; MIRN181 MICRORNA, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GENE THERAPY; CARCINOMATOSIS; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; EXON; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION; HEMATOPOIETIC CELL; HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRASPLENIC CARCINOMATOSIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; RNA ANALYSIS; RNA SPLICING; SUICIDE GENE; TRANSGENE; ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; DRUG SCREENING; GENE VECTOR; GENETICS; LIVER NEOPLASMS; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

MUS MUSCULUS;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, CATALYTIC; RNA, MESSENGER; TELOMERASE; TRANSGENES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919430025     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.006     Document Type: Article

References (47)

1. Sullenger B.A., Cech T.R. Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. Nature 1994, 371:619-622.
2. Jones J.T., Lee S.W., Sullenger B.A. Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells. Nat. Med 1996, 2:643-648.
3. Phylactou L.A., Darrah C., Wood M.A.J. Ribozyme-mediated trans-splicing of a trinucleotide repeat. Nat. Genet 1998, 18:378-381.
4. Lan N., Howrey R.P., Lee S.W., Smith C.A., Sullenger B.A. Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors. Science 1998, 280:1593-1596.
5. Rogers C.S., Vanoye C.G., Sullenger B.A., George A.L. Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J. Clin. Invest 2002, 110:1783-1789.
6. Shin K.S., Sullenger B.A., Lee S.W. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol. Ther 2004, 10:365-372.
7. Ryu K.J., Kim J.H., Lee S.W. Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing. Mol. Ther 2003, 7:386-395.
8. Jung H.S., Lee S.W. Ribozyme-mediated selective killing of cancer cells expressing carcinoembryonic antigen RNA by targeted trans-splicing. Biochem. Biophys. Res. Commun 2006, 349:556-563.
9. Won Y.S., Lee S.W. Targeted retardation of hepatocarcinoma cells by specific replacement of alpha-fetoprotein RNA. J. Biotechnol 2007, 129:614-619.
10. Ban G., Jeong J.S., Kim A., Kim S.J., Han S.Y., Kim I.H., et al. Selective and efficient retardation of cancers expressing cytoskeleton-associated protein 2 by targeted RNA replacement. Int. J. Cancer 2011, 129:1018-1029.
11. Won Y.S., Lee S.W. Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by trans-splicing ribozyme. J. Biotechnol 2012, 158:44-49.
12. Kwon B.S., Jung H.S., Song M.S., Cho K.S., Kim S.C., Kimm K., et al. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript. Mol. Ther 2005, 12:824-834.
13. Hong S.H., Jeong J.S., Lee Y.J., Jung H.I., Cho K.S., Kim C.M., et al. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cell. Mol. Ther 2008, 16:74-80.
14. Jeong J.S., Lee S.W., Hong S.H., Lee Y.J., Jung H.I., Cho K.S., et al. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model. Clin. Cancer Res 2008, 14:281-290.
15. Fukazawa T., Maeda Y., Sladek F.M., Owen-Schaub L.B. Development of a cancer-targeted tissue-specific promoter system. Cancer Res 2004, 64:363-369.
16. Song M.S., Jeong J.S., Ban G., Lee J.H., Won Y.S., Cho K.S., et al. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo. Cancer Gene Ther 2009, 16:113-125.
17. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
18. Yui J., Chiu C.P., Lansdorp P.M. Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood 1998, 91:3255-3262.
19. Forsyth N.R., Wright W.E., Shay J.W. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation 2002, 69:188-197.
20. Ring C.J., Harris J.D., Hurst H.C., Lemoine N.R. Suicide gene expression induced in tumor cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther 1996, 3:1094-1103.
21. Wu L., Johnson M., Sato M. Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol. Med 2003, 9:421-429.
22. Ahmed A., Thompson J., Emiliusen L., Murphy S., Beauchamp R.D., Suzuki K., et al. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat. Biotechnol 2003, 21:771-777.
23. Bagga S., Bracht J., Hunter S., Massirer K., Holtz J., Eachus R., et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 2005, 122:553-563.
24. Behm-Ansmant I., Rehwinkel J., Doerks T., Stark A., Bork P., Izaurralde E. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev 2006, 20:1885-1898.
25. Giraldez A.J., Mishima Y., Rihel J., Grocock R.J., Van Dongen S., Inoue K., et al. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science 2006, 312:75-79.
26. Wu L., Fan J., Belasco J.G. From the cover: microRNAs direct rapid deadenylation of mRNA. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4034-4039.
27. Hafner M., Landthaler M., Burger L., Khorshid M., Hausser J., Berninger P., et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PARCLIP. Cell 2010, 141:129-141.
28. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol 2005, 6:376-385.
29. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
30. Stefani G., Slack F.J. Small non-coding RNAs in animal development. Nat. Rev. Mol. Cell Biol 2008, 9:219-230.
31. Calin G.A., Croce C.M. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66:7390-7394.
32. Brown B.D., Venneri M.A., Zingale A., Sergi L., Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med 2006, 12:585-591.
33. Brown B.D., Gentner B., Cantore A., Colleoni S., Amendola M., Zingale A., et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol 2007, 25:1457-1467.
34. Brown B.D., Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet 2009, 10:578-585.
35. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
36. Ramkissoon S.H., Mainwaring L.A., Ogasawara Y., Keyvanfar K., McCoy J.P., Sloand E.M., et al. Hematopoietic-specific microRNA expression in human cells. Leuk. Res 2006, 30:643-647.
37. Georgantas R.W., Hildreth R., Morisot S., Alder J., Liu C.G., Heimfeld S., et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2750-2755.
38. Lee Y.J., Han S.R., Kim N.Y., Lee S.H., Jeong J.S., Lee S.W. An RNA aptamer that binds carcinoembryonic antigen inhibits hepatic metastasis of colon cancer cells in mice. Gastroenterology 2012, 143:155-165.
39. Schmitter D., Fikowski J., Sewer A., Pillai R.S., Oakeley E.J., Zavolan M., et al. Effects of dicer and argonaute down-regulation on mRNA levels in human HEK293 cells. Nucleic Acids Res 2006, 34:4801-4815.
40. Xiao C., Catado D.P., Galler G., Thai T.H., Patterson H.C., Wang J., et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007, 131:146-159.
41. Doench J.G., Petersen C.P., Sharp P.A. siRNAs can function as miRNAs. Genes Dev 2003, 17:438-442.
42. Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
43. Suzuki T., Sakurai F., Nakamura S., Kouyama E., Kawabata K., Kondoh M., et al. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol. Ther 2008, 16:1719-1726.
44. Luo Y., Zhu D. Combinatorial control of transgene expression by hypoxia-responsive promoter and microrna regulation for neural stem cell-based cancer therapy. Biomed. Res. Int 2014, 2014:751397.
45. Song M.S., Jeong J.S., Cho K.S., Lee S.W. Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme. Exp. Mol. Med 2007, 39:722-732.
46. Kim Y.H., Moon J.Y., Kim E.O., Lee S.J., Kang S.H., Kim S.K., et al. Efficient targeting and tumor retardation effect of pancreatic adenocarcinoma up-regulated factor (PAUF)-specific RNA replacement in pancreatic cancer mouse model. Cancer Lett 2014, 344:223-231.
47. Cho S., Jang I., Jun Y., Yoon S., Ko M., Kwon Y., et al. MiRGator v3.0: a microRNA portal for deep sequencing, expression profiling and mRNA targeting. Nucleic Acids Res 2013, 41:D252-D257.